Literature DB >> 17919852

Matrix metalloproteinases in infants with posthemorrhagic hydrocephalus.

Toshio Okamoto1, Satoru Takahashi, Eiki Nakamura, Ken Nagaya, Tokitsugi Hayashi, Masaru Shirai, Kenji Fujieda.   

Abstract

The cerebrospinal fluid matrix metalloproteinase (MMP) activities were measured in infants with posthemorrhagic hydrocephalus to elucidate the intrinsic mechanism for the resolution of ventricular dilation. Increased MMP-9 activities were observed in the patients who escaped a shunt operation, suggesting its potential contribution to the resolution of ventricular dilation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17919852     DOI: 10.1016/j.earlhumdev.2007.08.006

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  5 in total

Review 1.  Perinatal biomarkers in prematurity: early identification of neurologic injury.

Authors:  Maria Andrikopoulou; Ahmad Almalki; Azadeh Farzin; Christina N Cordeiro; Michael V Johnston; Irina Burd
Journal:  Int J Dev Neurosci       Date:  2014-04-24       Impact factor: 2.457

Review 2.  Inflammation in acquired hydrocephalus: pathogenic mechanisms and therapeutic targets.

Authors:  Jason K Karimy; Benjamin C Reeves; Eyiyemisi Damisah; Phan Q Duy; Prince Antwi; Wyatt David; Kevin Wang; Steven J Schiff; David D Limbrick; Seth L Alper; Benjamin C Warf; Maiken Nedergaard; J Marc Simard; Kristopher T Kahle
Journal:  Nat Rev Neurol       Date:  2020-03-09       Impact factor: 42.937

Review 3.  Biomarkers in neonatal posthemorrhagic hydrocephalus.

Authors:  Stephanie Merhar
Journal:  Neonatology       Date:  2011-07-27       Impact factor: 4.035

Review 4.  Nonsurgical therapy for hydrocephalus: a comprehensive and critical review.

Authors:  Marc R Del Bigio; Domenico L Di Curzio
Journal:  Fluids Barriers CNS       Date:  2016-02-05

5.  Biomarkers of brain injury in the premature infant.

Authors:  Martha Douglas-Escobar; Michael D Weiss
Journal:  Front Neurol       Date:  2013-01-22       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.